Nutriband INC 10-K annual reports

Nutriband Inc. has filed an amendment to its 2026 Form 10-K to include its Executive Compensation Clawback Policy, adopted in compliance with NASDAQ listing standards and SEC Rule 10D-1.

Nutriband Inc. filed its annual report for the fiscal year ended January 31, 2026, detailing progress on its AVERSA Fentanyl abuse-deterrent transdermal system and financial performance from its contract manufacturing segment.

Nutriband Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended January 31, 2025, with updated exhibits and certifications.

Nutriband Inc.'s 10-K filing reveals a widened net loss for fiscal year 2025, driven by increased research and development expenses for its AVERSA Fentanyl product and an impairment charge, despite a slight revenue increase.

Nutriband Inc. files its annual report, detailing financial results and progress in developing its AVERSA abuse-deterrent transdermal technology.